Repurposed drug yields unprecedented response rates in metastatic lung cancer
A targeted therapy resurrected by the Moon Shots Program™ at MD Anderson has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries a highly treatment-resistant mutation.
In a Phase II clinical trial, the drug poziotinib has shrunk tumors by at least 30% in eight of 11 (73%) non-small cell lung cancer patients whose cancer includes an epidermal growth factor receptor...
MD Anderson named site of NIH immunotherapy research center
A major national effort to expand the reach of cancer immunotherapy in order to benefit more patients will draw upon the expertise...
'I’ve seen suffering and dying from an avoidable disease'
In Texas, the number is even lower. Only 33% of Texas teens were up to date. That’s a lot of room for improvement.
Having spent the...
MD Anderson pancreatic cancer researcher to lead Dream Team
Deeply entrenched and mature by the time it’s found, pancreatic cancer is one of the hardest types of the disease to defeat. A Dream Team assembled by Stand Up to Cancer and led by an investigator at MD Anderson Cancer Center will test new ways to find the disease in its emerging, more vulnerable phase in people who are at high risk for developing it.
“Our plan is to intercept pancreatic cancer by finding it and stopping it before...
5 years in, Moon Shots Program is primed for continued progress
It's been five years since MD Anderson launched its Moon Shots Program™, a collaborative effort to more quickly turn scientific discoveries...
Hydrocodone prescriptions decreasing, study shows
The effectiveness of opioids in treating cancer pain has been well established over the years. But today’s opioid epidemic that began slowly...